RGENIX to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
New York, NY – November 23, 2020 – RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that CEO Masoud Tavazoie, M.D., Ph.D., will present at the 32nd Annual Piper Sandler Virtual Healthcare Conference.
This virtual presentation will be available online here from November 23, 2020 at 10:00 AM EST to December 3, 2020.
A link to an archived version of this presentation will also be available on RGENIX’s website within the News section.
Rgenix will also be participating in one-on-one meetings with investors on November 30 and December 1, meetings may be requested exclusively via Piper Sandler.
RGENIX, Inc., is a privately-held clinical-stage biopharmaceutical company focused on the discovery and development of novel cancer drugs that target key pathways in cancer progression. The company is pursuing several first-in-class drug candidates to treat cancers of high unmet need. RGENIX identifies novel cancer targets using a microRNA-based target discovery platform originally developed by RGENIX’s scientific co-founders at The Rockefeller University and now exclusively licensed to RGENIX. The company brings together distinguished scientific founders, a seasoned Board, and a leadership team comprised of experienced drug developers. The company is funded by leading biotechnology investors, including Novo Holdings A/S, Sofinnova Partners, Lepu Holdings Limited, Oceanpine Capital, WuXi PharmaTech Healthcare Fund I, LP, Alexandria Venture Investments, LLC, Exor Seeds, and the Partnership Fund for New York City. For more information, please visit www.rgenix.com.